Editorial

Ongoing Studies of the Bladder Tumor Study Group: An Overview
  • N. Aydın Mungan
  • İlker Tınay
Bull Urooncol 2014; 13: 67-69 DOI: 10.4274/UOB.01

Review

Is radical cystectomy the gold standard?
  • Binhan Kağan Aktaş
  • Ali Memiş
Bull Urooncol 2013; 12: 1-5
Bladder cancer epidemiology in the world and in Tukey
  • Sultan Eser
  • Raziye Özdemir
Bull Urooncol 2012; 11: 1-9
Robotic surgery in radical cystectomy
  • Yakup Kordan
  • Burhan Coşkun
Bull Urooncol 2013; 12: 6-10
Genetik alteration in bladder carcinoma
  • Hakan Akça
  • Onur Tokgün
Bull Urooncol 2012; 11: 10-13
Geometry of cancer and fractals in bladder cancer
  • Fehmi Narter
  • Osman Köse
Bull Urooncol 2013; 12: 11-17
Positron Emission Tomography/Computed Tomography in Bladder Carcinoma
  • Recep Bekiş
  • Emine Acar
  • Uğur Mungan
Bull Urooncol 2015; 14: 13-17 DOI: 10.4274/uob.236
The approaches in uncommon malignant tumours of the bladder
  • Hayrettin Şahin
Bull Urooncol 2012; 11: 14-18
The Relationship between Bladder Cancer and Epigenetic Alterations
  • Ata Özen
  • Ali Ülgen
  • Cavit Can
Bull Urooncol 2017; 16: 17-21 DOI: 10.4274/uob.566
Second-TUR
  • Ali Feyzullah Şahin
  • Rauf Taner Divrik
Bull Urooncol 2013; 12: 18-21
BCG suşlarının tedavi edici etkinlik farkı var mı?
  • Hayrettin Şahin
Bull Urooncol 2011; 10: 18-20
The Risk Stratifications in Non-Muscle Invasive Bladder Cancer: How Much Accurate are the Methods That We Use? A Multi-Directional View
  • Barış Kuzgunbay
  • Yıldırım Bayazıt
Bull Urooncol 2015; 14: 18-22 DOI: 10.4274/uob.275
What is the current status of bladder tumor markers?
  • İbrahim Dönmez
  • N. Aydın Mungan
Bull Urooncol 2012; 11: 19-26
İdame BCG kime uygulanmalı nasıl uygulanmalı?
  • Çetin Volkan Öztekin
  • Veli Erşahin
Bull Urooncol 2011; 10: 21-22
Is intravesical BCG treatment necessary and/or sufficient?
  • Sinan Ekici
  • Polat Türker
Bull Urooncol 2013; 12: 22-25
The Role of Radiology in Perivesical Invasion of Muscle-Invasive Bladder Cancer
  • İbrahim İlker Öz
  • Aydın Mungan
Bull Urooncol 2016; 15: 22-25 DOI: 10.4274/uob.550
BCG komplikasyonları ve başa çıkma
  • Uğur Yücetaş
  • Gökhan Toktaş
Bull Urooncol 2011; 10: 23-25
Radical Cystectomy in Elderly Patients: Predicting Complications and Mortality, Technical Aspects and Postoperative Care
  • Uğur Kuyumcuoğlu
  • Kaan Özdedeli
Bull Urooncol 2015; 14: 23-28 DOI: 10.4274/uob.280
Nutritional evaluation of patients who are candidate for radical cystectomy
  • Osman Köse
  • Öztuğ Adsan
Bull Urooncol 2013; 12: 26-30
Flüoresan sistoskopi ve tur'un geleceği var mı?
  • Gökhan Özer
Bull Urooncol 2011; 10: 26-30
Which Patients Should Undergo Immediate or Deferred Cystectomy in Non-Muscle Invazive Bladder Cancer? Evaluation of...
  • Şenol Tonyalı
  • Mustafa Sertaç Yazıcı
Bull Urooncol 2016; 15: 26-30 DOI: 10.4274/uob.536
Experimental Bladder Cancer Models for Animals
  • Murat Koşan
  • Aydın Mungan
Bull Urooncol 2015; 14: 29-32 DOI: 10.4274/uob.283
Should all patients with non-muscle invaziv bladder tumor receive postoperative early single dose intravesical chemotherapy?
  • Sümer Baltacı
  • Ömer Gülpınar
Bull Urooncol 2012; 11: 30-33
Limited-standard-extended lymphadenectomy in bladder cancer
  • Hayrettin Şahin
Bull Urooncol 2013; 12: 31-35
Bipolar veya plazmakinetik enerji ile yapılan TUR-M operasyonlarının klasik metottan farkı var mı?
  • Binhan Kağan Aktaş
  • Mehmet Murat Baykam
Bull Urooncol 2011; 10: 31-34
Synchronous and Metachronous Secondary Tumors of Bladder Cancer Patients
  • Ayhan Dirim
  • Hakan Özkardeş
  • Eray Hasırcı
Bull Urooncol 2016; 15: 31-37 DOI: 10.4274/uob.545
Approach to the complications of intravesical therapy in bladder cancer
  • Turgay Gülecen
  • Cüneyd Özkürkçügil
Bull Urooncol 2012; 11: 34-40
Dev Ta Tümörde TUR nasıl Yapılmalıdır?
  • Taylan Oksay
Bull Urooncol 2011; 10: 35-37
Bladder cancer and genetics
  • Ata Özen
  • Cavit Can
Bull Urooncol 2013; 12: 36-42
TUR'a bağlı mesane perforasyonu: tedavi ve izlem
  • Kürsad Zengin
  • Sinan Başay
Bull Urooncol 2011; 10: 38-40
Screening for Bladder Cancer: Reliability and Limitations
  • Kamil Fehmi Narter
  • Cahit Şahin
Bull Urooncol 2015; 14: 38-45 DOI: 10.4274/uob.238
Importance of mycobacteria in treatment of bladder tumor
  • Esra Büber
  • Selçuk Keskin
  • N. Leyla Açan
Bull Urooncol 2012; 11: 41-45
Parsiyel sistektomiyi unuttuk mu?
  • C. Serkan Gökkaya
  • Ali Memiş
Bull Urooncol 2011; 10: 41-44
Nursing care following radical cystectomy and urinary diversion
  • Cemile Ulubay Akkaya
Bull Urooncol 2013; 12: 43-45
Kadın sistektomisinde histerektomi ve vajinal kaf çıkarma ayrılmaz bir parça mıdır? Neden?
  • Süleyman Bulut
Bull Urooncol 2011; 10: 45-47
Supportive treatment for patient receiving gemsitabine-cisplatine and suggestions for nursing
  • Yeter Kırdal
Bull Urooncol 2013; 12: 46-49
Is it possible to predict BCG effectivity in the treatment of superficial bladder cancer? Are there any markers?
  • Polat Türker
  • Sinan Ekici
Bull Urooncol 2012; 11: 46-51
History of Urologic Oncology in Turkey: Bladder Cancers
  • Yaşar Bedük
Bull Urooncol 2015; 14: 46-49 DOI: 10.4274/uob.295
Diagnosis and management of the strictures after prostatectomy
  • Murat Akand
  • Serdar Göktaş
Bull Urooncol 2011; 10: 48-51
Genişletilmiş lenfadenektomi standart bir tedavi olmalı mı?
  • Ömer Gökhan Doluoğlu
  • Mehmet Karabakan
Bull Urooncol 2011; 10: 48-50
Experimental animal models for bladder cancer
  • Şevket Tolga Tombul
  • Talha Müezzinoğlu
Bull Urooncol 2013; 12: 50-53
Non-Muscle Invasive Bladder Cancer: Diagnosis and Treatment of Highest-Risk Subgroup
  • Yılören Tanıdır
  • İlker Tınay
Bull Urooncol 2015; 14: 50-54 DOI: 10.4274/uob.298
Açık, laparoskopik ve robotik sistektomi: avantaj ve dezavantajları
  • Bülent Altunoluk
Bull Urooncol 2011; 10: 51-54
Is TUR-B operations can be done in the office conditions by using local anesthesia
  • Tansu Değirmenci
  • Bülent Günlüsoy
Bull Urooncol 2012; 11: 52-54
Radiological methods that aid in the diagnosis of bladder cancer
  • Fatih Kantarcı
  • Deniz Çebi Olgun
  • Atilla Süleyman Dikici
Bull Urooncol 2013; 12: 54-57
Can Bladder be Preserved with TURB + Chemotherapy instead of Radical Surgery (Can we Preserve the Bladder from Cancer)
  • Cavit Can
Bull Urooncol 2012; 11: 55-57
Quality of Life after Radical Cystectomy and Diversion
  • Gökhan Toktaş
  • Emre Karabay
Bull Urooncol 2015; 14: 55-60 DOI: 10.4274/uob.299
Risk Adaptive Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
  • Elif Atağ
  • Aziz Karaoğlu
  • Ömer Küçük
Bull Urooncol 2017; 16: 57-62 DOI: 10.4274/uob.763
Neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
  • Aziz Karaoğlu
  • Utku Oflazoğlu
  • Necla Demir
Bull Urooncol 2013; 12: 58-63
Role of Nanoparticles in the Treatment of Noninvasive Bladder Cancer
  • Erem Bilensoy
  • Nazlı Erdoğar
  • Aydın N. Mungan
Bull Urooncol 2015; 14: 61-66 DOI: 10.4274/uob.246
Targeted Therapies in Metastatic Bladder Cancer: Has It Been Approved as a Treatment Option Nowadays?
  • Nil Molinas Mandel
Bull Urooncol 2015; 14: 67-70 DOI: 10.4274/uob.2015.14.001
How Can One Define the Surgical Quality of Radical Cystectomy?
  • Mesut Altan
  • Burhan Özdemir
  • Burak Çıtamak
  • Bülent Akdoğan
  • Haluk Özen
Bull Urooncol 2014; 13: 70-74 DOI: 10.4274/UOB.02
Surgical Approaches in Patients with Metastatic Bladder Cancer: Metastasectomy and Palliative Cystectomy
  • Utku Lokman
  • Özgür Uğurlu
Bull Urooncol 2014; 13: 75-78 DOI: 10.4274/UOB.03
Comparison of the Clinical and Pathologic Staging in Patients Undergoing Radical Cystectomy, the Factors Associated with Upstaging and its Effect on Outcome
  • Polat Türker
Bull Urooncol 2014; 13: 84-87 DOI: 10.4274/UOB.05
Transurethral Resection of Bladder Cancer (TUR-B) for Non-Muscle Invasive Bladder Cancer: How to Reach Excellence?
  • Mehmet İlker Gökçe
  • Yaşar Bedük
Bull Urooncol 2014; 13: 88-92 DOI: 10.4274/UOB.06
Relationship Between Human Papilloma Virus and Bladder Cancer
  • Osman İnci
  • Ebru Taştekin
  • Hakan Akdere
Bull Urooncol 2017; 16: 92-94 DOI: 10.4274/uob.556
Which Treatment Should We Prefer for High-Risk Nonmuscle Invasive Bladder Cancer? Early Cystectomy or Bladder Sparing?
  • Ali Furkan Batur
  • Sinan Sözen
Bull Urooncol 2014; 13: 93-98 DOI: 10.4274/UOB.07
The Approach to High Risk Bladder Cancers in The Absence of Bacillus Calmette Guérin: What should Be the Treatment and Follow Up?
  • Polat Türker
  • Levent Türkeri
Bull Urooncol 2014; 13: 103-108 DOI: 10.4274/UOB.09
Controversies in Radical Cystectomy: Meta-Analysis and Systemic Comparison of Open Surgery with Laparoscopic and Robotic Surgery
  • Mehmet Kaynar
  • Serdar Göktaş
Bull Urooncol 2016; 15: 107-112 DOI: 10.4274/uob.542
Does Urinary Cytology Find the Value in the Detection and Follow-up of Urinary Bladder Cancer?
  • Kutsal Yörükoğlu
Bull Urooncol 2014; 13: 109-112 DOI: 10.4274/UOB.10
Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis of Patients with Non-Muscle Invasive Bladder Cancer: A Review Based on Meta-Analysis
  • Emre Tüzel
Bull Urooncol 2014; 13: 113-118 DOI: 10.4274/UOB.11
Bladder Perforation During TUR of Non Muscle Invasive Bladder Tumours: Early and Late Management
  • Deniz Arslan
Bull Urooncol 2014; 13: 119-121 DOI: 10.4274/UOB.12
Rare Benign and Uncertain Malignant Potential Tumors of Bladder: Review of the Literature
  • Cem Yücel
  • Mehmet Zeynel Keskin
Bull Urooncol 2017; 16: 123-126 DOI: 10.4274/uob.673
Tumor Like Lesions of the Bladder
  • Şeyda Erdoğan
  • Emine Kılıç Bağır
Bull Urooncol 2015; 14: 254-257 DOI: 10.4274/uob.493
Diagnostic and Prognostic Molecular Features of Urothelial Bladder Cancer and New Treatment Approaches
  • Zafer Küçükodacı
  • Kutsal Yörükoğlu
Bull Urooncol 2015; 14: 258-270 DOI: 10.4274/uob.366